The Cannigma

MAY 19, 2021

While many countries around the world have legalized or decriminalized cannabis or have eased up on enforcement in recent years, in Japan in 2018 there was a sharp increase in cannabis-related arrests — and 80% of them were possession charges. of Japanese have reported consuming cannabis, as opposed to more than 40% in the US and Canada.

Law

The Cannigma

MARCH 18, 2021

Taken together, the lack of guidance and lack of information about what treatments patients are taking, may underlie “inconsistencies in both use and reported effectiveness,” the researchers stated. Here are the most interesting statistics from the survey. “If

Patients

Puff Puff Post

DECEMBER 28, 2018

The Current Treatments for Autism. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. Instead, CBD is being used.

Treatment

The Cannigma

MARCH 7, 2022

What can the current clinical trials tell us? A common theme with cannabis is that more research is needed, so thankfully there are clinical trials in the works looking at the therapeutic utility of CBN. Those enrolled in the study will receive 28 days of treatment and then be assessed by pain-rating scales.

THC

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate revenue of $151.7

Chronic Pain

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.

Research and Development

Veriheal

OCTOBER 20, 2023

Michigan’s decision to end pre-employment drug testing is motivated by the fact that the state already legalized recreational cannabis back in 2018. The vote represents the employees’ desire for fair treatment and recognition for their efforts within the industry.

Policy

Cannabis Law Report

JANUARY 14, 2022

Right-to-try aims to allow patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain unapproved treatments. Right-to-try permits those patients to have access to investigational drugs.

Treatment

CannaTech

SEPTEMBER 23, 2019

In the UK, cannabis-based medicinal products (CBMP) were legalized in November 2018. This bottleneck has left patients and parents to pursue unregulated avenues to access treatment. Furthermore, pharmaceutical companies often fund and initiate randomised clinical trials to validate their drugs.

Patients

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. Dr. Eric Hollander, the Director of the Autism and Obsessive Compulsive Spectrum Program and Anxiety and Depression Program at Montefiore Hospital, is leading the clinical trial.

Clinical Trials

Peninsula Alternative Health

MAY 15, 2019

Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. Of 272 combined patients, 86% experienced some clinical benefit, and 10% experienced a complete clinical response. tetrahydrocannabinol (THC).

Conditions

Canna Law Blog

MARCH 4, 2020

In recent years, the United States has seen a proliferation of ketamine clinics. From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs.

Legalization

Cannabis Info

OCTOBER 11, 2019

Cannabis & Dementia: New Study Explores Pot’s Potential for Treatment. In the decades since the medical marijuana movement began in earnest in the 1970s, cannabis has been anecdotally touted as an effective treatment for a variety of illnesses, including those impacting brain function, such as seizures, anxiety and depression.

Treatment

Cannabis Law Report

SEPTEMBER 1, 2021

The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. His background is a mix of cognitive psychology, clinical psychology and computer science. After Approval, It’s Off to Treatment Clinics.

Research and Development

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

The first-ever cannabis-based drug with FDA approval is Epidiolex*, a new prescription drug designed to treat severe seizure disorders that do not respond to other treatments. After securing FDA approval in June of 2018, Epidiolex’s manufacturer GW Pharma announced the drug should enter the consumer market by the end of 2018.

Research and Development

Puff Puff Post

OCTOBER 3, 2019

The possibility of treating the symptoms associated with autism originated when the FDA approved Epidoliolex in 2018. Not only did the success influence the European Commission to approve Epidoliolex , but it also sparked motivation to develop a similar treatment for other disorders.

Research and Development

Cannabis Law Report

AUGUST 21, 2019

Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. If you wish to re-publish this story please do so with following accreditation. AUTHOR: Mark Taylor.

Clinical Trials

The Cannigma

MARCH 25, 2021

When the law changed in the UK in 2018, I was humbled by the efforts of those who suffer on a daily basis to achieve legal access to medicinal cannabis. I also advocated alongside my partner for many years as part of the patient group United Patients Alliance. I remain in awe of these patients to this day.

Patients

Cannabis Law Report

JULY 6, 2021

Professor Allan Young, Head of Academic Psychiatry at King’s IoPPN, said, “We have been in partnership with SLaM at the Maudsley Biomedical Research Centre since 2007, and with COMPASS on COMP360 psilocybin therapy research since 2018. George Goldsmith, CEO and Co?founder,

Research and Development

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. Neurological Disorders: Several cannabinoids show promise in the treatment of neurological disorders, including multiple sclerosis (MS) and Parkinson’s disease.

Cannabinoids

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. In May 2018, the federal Right to Try Act (the “Act”) was signed into law. Id ; 21 CFR 312.1-10;

Law

Cannabis Law Report

JANUARY 3, 2022

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that the first patient has been dosed in a Phase 2 proof-of-concept clinical study investigating ANEB-001 as a potential treatment for acute cannabinoid intoxication.

Pharmaceutical

CannaMD

AUGUST 26, 2020

Current Cocaine Treatments. As researchers point out: There is no gold standard pharmacological treatment for dependence on cocaine. Although several drugs have been investigated, there is no strong or consistent evidence indicating any of these drugs for the treatment of cocaine use disorder. mice/rats).

Therapy

The Cannigma

JUNE 23, 2022

Another study published in 2018 investigated the effects of CBD/CBDA and CBG/CBGA on aldose reductase, an enzyme responsible for glucose formation. And while some are hopeful for the potential of CBGA, most experts are not yet convinced of cannabinoids as prevention or treatment of COVID infections. Where can you buy CBGA?

Cannabinoids

CannaMD

NOVEMBER 15, 2020

research on marijuana harms – such as cannabis withdrawal, treatments for substance abuse and use/exposure during pregnancy or infancy – received 20 times more funding than research on cannabis therapeutics. While some funds are being used to study cannabis medical treatments, the majority of funding is still used to research harms.

DEA

Cannabis Law Report

DECEMBER 14, 2019

million in the Melbourne cannabis firm in 2018. Export markets have also continued to open up, according to Bell and Smith, since the shipment of the drug out of the country was legalized in 2018. A 2018 report from Prohibition Partners has forecasted that medical cannabis in Australia could be worth US$2.13

Pharmaceutical

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Silver Spring, MD: US Food and Drug Administration; June 25, 2018.

CBD

Medical Marijuana Program Connection

JANUARY 16, 2024

Rowena Naylor/Stocksy United Cannabidiol (CBD) has been approved for use in the treatment of two early-onset, intractable forms of epilepsy, Dravet syndrome and Lennox-Gastaut syndrome, since 2018. This decision followed clinical trials showing. Read More

Clinical Trials

CannaMD

NOVEMBER 8, 2019

VA providers can and do discuss marijuana use with veterans as part of comprehensive care planning, and adjust treatment plans as necessary. VA health care providers will record marijuana use in the veteran’s VA medical record in order to have the information available in treatment planning. VidaCann : 15% discount.

Marijuana

MedicalJane

JUNE 29, 2018

On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. branch of Aphria, Inc.,

Clinical Trials

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression.

Clinical Trials

The Cannigma

MAY 6, 2021

Other than serving as a lighter version of delta-9-THC, delta-8 has also been researched as a potential treatment for a number of medical conditions and symptoms such as vomiting and nausea, glaucoma, pain, and inflammation. The only clinical trial on delta-8-THC involving humans was done on children in Israel in 1995.

THC

CannaMD

AUGUST 8, 2020

More recently, the 2018 Farm Bill expanded hemp legislation. 27, 2018, the DEA announced a rule change that placed “FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 On June 25, 2018, Epidiolex became the first FDA approved cannabis-derived medication to hit U.S. In 1970, the U.S.

CBD

Cannabis Law Report

OCTOBER 20, 2021

Mr Blunt said it had “exciting potential” for the treatment of mental health conditions such as depression, trauma and addiction. It would then potentially be in the same category as medical cannabis, which was legalised in 2018.

Supply Chain

Cannabis Law Report

NOVEMBER 12, 2021

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022. Dr John Lucas (CEO).

Cannabinoids

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression.

Law

SpeedWeed

DECEMBER 28, 2018

In my defense, 2018 has been a wild ride in the world of weed, a 12-month timespan which truly could be called “the best of times and the worst of times,” or perhaps just the highest and lowest of times. The Top 10 Cannabis Stories of 2018. But until then, here are the buzzes and bummers 2018 had to offer.

Pharmaceutical